Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 17/20 | 0.43 |
| ▸ | KIT | P10721 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15418535 | 0.87 | CYP1A2 (0.39) | CSF1RKITCYP1A2 | |
| SCHEMBL15418312 | 0.85 | CSF1R (0.43) | CSF1RKIT | |
| SCHEMBL3087471 | 0.79 | CSF1R (0.51) | CSF1RKIT | |
| SCHEMBL5653584 | 0.79 | CSF1R (0.60) | CSF1RKIT | |
| SCHEMBL4181729 | 0.78 | CSF1R (0.54) | CSF1RKIT | |
| SCHEMBL3090219 | 0.76 | CSF1R (0.55) | CSF1RKIT | |
| SCHEMBL14384891 | 0.75 | CSF1R (0.57) | CSF1RKIT | |
| SCHEMBL4187630 | 0.75 | CSF1R (0.56) | CSF1RKIT | |
| SCHEMBL4186847 | 0.73 | CSF1R (0.55) | CSF1RKIT | |
| SCHEMBL3903334 | 0.73 | CSF1R (0.41) | CSF1RKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452996-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-27 | — | — | US | disclosed |
| EP-2021329-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-13 | — | — | EP | disclosed |
| US-20160046602-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| US-9221797-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-29 | — | — | US | disclosed |
| US-20140148448-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
| EP-2687516-A1 | Inhibitors of C-FMS Kinase | Janssen Pharmaceutica N.V. (BE) | 2014-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148448-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | CSF1R 58/4885KIT 114/4885CYP1A2 3774/4885 |
| US-20160046602-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | CSF1R 58/4885KIT 114/4885CYP1A2 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.